Epcoritamab-CAR T Cells for Large B-cell Lymphomas
This study tests whether epcoritamab, a type of cancer-fighting protein, can improve the effectiveness of CAR T cell therapy for non-Hodgkin's lymphomas. Patients will receive epcoritamab either before CAR T cell treatment or if their lymphoma returns after the CAR T cells.
Key Objective: The trial investigates whether epcoritamab can improve CAR T cell effectiveness and help control lymphoma that remains after CAR T treatment.
Who to Consider: Patients with large B-cell lymphomas who are candidates for CAR T cell therapy should consider enrolling.
Trial Parameters
Brief Summary
This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years * Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally authorized representative (or decision maker when there is not an advanced directive in place) must be willing to provide informed consent on behalf of the patient. * Able to comply with the study protocol, in the investigator's judgment * ECOG PS of 0 - 2 * Pathology report confirming eligible diagnosis * Documented CD20+ tumor cells on most recent biopsy * Patients will have failed to respond to frontline standard of care therapy containing an anthracycline and anti-CD20 antibody * Patients will be eligible and consent to be treated with a "commercially available" anti-CD19, 4-1BB, CD3zeta CAR-T cell therapy or anti-CD19, CD28, CD3zeta CAR T cell therapy (for example, tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene maraleucel) * Patients must have a PET/CT scan (preferred), diagnostic CT sc